Breaking Finance News

A statement released earlier today by RBC Capital about AcelRx (NASDAQ:ACRX) bumps down the target price to $5.00

Stating a potential upside of 1.33%, RBC Capital lowered the target price of AcelRx (NASDAQ:ACRX) to $5.00

On Friday July 14, 2017, Jefferies Group LLC released a statement on AcelRx (NASDAQ:ACRX) bumped up the target price from $0.00 to $7.00 that suggested an upside of 2.07%.

Boasting a price of $2.15, AcelRx (NASDAQ:ACRX) traded -59.81% lower on the day. With the last close down -27.73% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. AcelRx has recorded a 50-day average of $3.80 and a two hundred day average of $2.97. Volume of trade was up over the average, with 24,274,300 shares of ACRX changing hands over the typical 2,214,920

Performance Chart

AcelRx (NASDAQ:ACRX)

With a total market value of $0, AcelRx has with a one year low of $1.95 and a one year high of $5.75 .

A total of 4 analysts have issued a report on the stock. 1 broker rating the stock a strong buy, 3 brokerages rating the stock a buy, 2 firms rating the stock a hold, 0 analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $7.63.

Brief Synopsis About AcelRx (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *